Union Therapeutics starts phase II trial of nasal spray for Covid-19 patients
Biotech company Union Therapeutics is testing its candidate niclosamide as a nasal spray for patients infected with Covid-19 who are either asymptomatic or mildly symptomatic in a phase II study.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
The Danish biotech company Union Therapeutics has enrolled the first patient in its phase II trial of drug candidate niclosamide as a treatment for Covid-19 patients, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Covid-19 treatment approved for human trials
For subscribers
EMA to investigate Covid-19 treatment
For subscribers
.jpg&w=384&q=75)
